In a 12-month randomized, open-label, prospective trial of 51 subjects with T2DM, empagliflozin yielded a 54% reduction in hs-CRP compared with placebo [237], and a 6-month intervention in patients with T2DM with coronary artery disease also reported a significant decrease in CRP [238]. This evidence concerns the gene CRP and coronary artery disorder.